This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
=== Occurrence of other cyclopropane fatty acids === The biosynthesis and occurrence of lactobacillic acid is closely linked to dihydrosterculic acid (compare sterculic acid), which is also a saturated fatty acid with the molecular formula C19H36O2, which contains a cyclopropane ring. Here, however, the ring is located at positions 9 and 10 of the carbon chain, which is why it is also referred to as cis-9,10-methylenoctadecanoic acid. Dihydrosterculic acid is also found in the lipids of many bacterial genera, but has also been found in eukaryotes, for example in protozoa from the Trypanosomatida group, here in the genera Crithidia, Leishmania, Leptomonas, Herpetomonas and Phytomonas. According to a study published in 2014, lactobacillic acid and dihydrosterculic acid are also found in cow's milk in very small quantities (< 0.1% of total fatty acids), but not in the milk of goats or sheep.
Also, by changing economic incentives, precision agriculture may hinder environmental policies' effectiveness: "Precision agriculture can lead to higher marginal abatement costs in the form of forgone profits, decreasing producers' responsiveness to those policies." In other words, holding pollution constant, precision agriculture allows a farmer to produce more output, making abatement more expensive. Off-farm, digital agriculture has the potential to improve environmental monitoring and food system traceability. The monitoring costs of certifying compliance with environmental, health, or waste standards are falling because of digital technology. For example, satellite and drone imagery can track land use and/or forest cover; distributed ledger technologies can enable trusted transactions and exchange of data; food sensors can monitor temperatures to minimize contamination during storage and transport. Together, technologies like these can form digital agriculture traceability systems, which allow stakeholders to track agri-food products in near-real-time. Digital traceability yields a number of benefits, environmental and otherwise:
Malaysia is the 66th largest country by total land area, with a total area of 330,803 km2 (127,724 sq mi). West Malaysia shares land borders with Thailand, while East Malaysia shares land borders with Indonesia and Brunei. Singapore is separated from the West by the Straits of Johor and is linked to it by a narrow causeway and a bridge. The country also shares maritime boundaries with Indonesia, Vietnam and the Philippines. The land borders are defined in large part by geological features such as the Perlis River, the Golok River and the Pagalayan Canal, whilst some of the maritime boundaries are the subject of ongoing contention. Brunei forms what is almost an enclave in Malaysia, with the state of Sarawak dividing it into two parts. Malaysia is the only country with territory on both the Asian mainland and the Malay Archipelago. The Strait of Malacca, lying between Sumatra and Peninsular Malaysia, is one of the most important thoroughfares in global commerce, carrying 40% of the world's trade. The southernmost point of mainland Asia is located at Tanjung Piai, in the state of Johor. The two parts of Malaysia, separated from each other by the South China Sea, share a largely similar landscape in that both Peninsular and East Malaysia feature coastal plains rising to hills and mountains. Peninsular Malaysia, containing 40% of Malaysia's land area, extends 740 km (460 mi) from north to south, and its maximum width is 322 km (200 mi).
Sources: en.wikipedia.org
Hypotonia (floppiness) Developmental delay Oculogyric crises Difficulty with initiating and controlling movements Dystonia and dyskinesia Gastointestinal dysmotility which can present at as vomiting, gastro-oesophageal reflux, diarrhoea and/or constipation Autonomic symptoms including difficulties controlling temperature and blood sugar, excessive sweating and nasal congestion Some people may develop cerebral folate deficiency, because O-methylation of the excessive amounts of L-DOPA can deplete methyl donors such as S-adenosyl methionine and levomefolic acid. This deviation can be detected by measuring the levels of levomefolic acid in the cerebrospinal fluid, and can be corrected by folinic acid.
. For electrical circuits, let n be the concentration of free charged particles (in m−3) and let q* be the charge of each particle (in coulombs). (For electrons, q* = e = 1.6×10−19 C.) Then nQ is the number of particles in the volume Q, and nQq* is their total charge. This is the charge that flows through the cross section per unit time, i.e. the current I. Therefore, I = nQq*. Consequently, Q = I/nq*, and
== A proposed model – actoclampins track filament ends == One proposed model suggests the existence of actin filament barbed-end-tracking molecular motors termed "actoclampins". The proposed actoclampins generate the propulsive forces needed for actin-based motility of lamellipodia, filopodia, invadipodia, dendritic spines, intracellular vesicles, and motile processes in endocytosis, exocytosis, podosome formation, and phagocytosis. Actoclampins also propel such intracellular pathogens as Listeria monocytogenes, Shigella flexneri, Vaccinia and Rickettsia. When assembled under suitable conditions, these end-tracking molecular motors can also propel biomimetic particles. The term actoclampin is derived from acto- to indicate the involvement of an actin filament, as in actomyosin, and clamp to indicate a clasping device used for strengthening flexible or moving objects, and for securely fastening two or more components, followed by the suffix -in to indicate its protein origin. An actin filament end-tracking protein may thus be termed a clampin. Dickinson and Purich recognized that prompt ATP hydrolysis could explain the forces achieved during actin-based motility. They proposed a simple mechano-enzymatic sequence known as the Lock, Load & Fire Model, in which an end-tracking protein remains tightly bound (locked or clamped) onto the end of one sub-filament of the double-stranded actin filament.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.